JBCPL gets trademark assignment of heart failure drug Azmarda from Novartis
Advertisement
JB Chemicals and Pharmaceuticals (JBCPL) has recently announced that the company has approved the assignment of trademark for Azmarda indicated for heart failure patients with reduced ejection fraction (HFrEF) from Novartis AG, Switzerland for India.
Azmarda is a brand of sacubitril/valsartan, the first-in-class angiotensin receptor neprilysin inhibitor (ARNI) presently approved for the treatment of heart failure with reduced ejection fraction (HFrEF).
For more information, check out the full story on the link below:
JBCPL Gets Trademark Assignment Of HF Drug Azmarda From Novartis For Rs 246 Crores
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.